Previous 10 | Next 10 |
– Phase 2 open-label CONNECT1-EDO51 study expected to be initiated in Canada in the first half of 2023 – – Potentially registration-directed, randomized, double-blind, placebo-controlled Phase 2 CONNECT2-EDO51 multinational study expected to be initiated in the seco...
BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McA...
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will pres...
2023-04-14 13:30:11 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch for a full list of events planned for the week or the Seeking Alpha earnings calendar for com...
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James M...
2023-03-25 10:58:06 ET PepGen Inc (PEPG) Q4 2022 Earnings Conference Call March 23, 2023 16:30 ET Company Participants Noel Donnelly - Chief Financial Officer James McArthur - President and Chief Executive Officer Jaya Goyal - Executive Vice President, Research a...
2023-03-23 16:14:31 ET PepGen press release ( NASDAQ: PEPG ): Q4 net loss of $14.9M. Cash and cash equivalents were $181.8 million as of December 31, 2022, which is anticipated to fund operations into early 2025. For further details see: PepGen reports Q4 results
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial res...
- In NHP, four monthly doses of 20 mg/kg of PGN-EDO51 resulted in 34.9% exon skipped transcripts in biceps; a 14-fold increase over the 2.5% exon 51 skipped transcripts observed after a single dose – - Following on the EDO51 Phase 1 study, we anticipate initiating in the ...
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James M...
News, Short Squeeze, Breakout and More Instantly...
2024-07-06 15:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of...
Michelle Mellion, M.D., promoted to Chief Medical Officer Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of t...